FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name a	2. Issuer Name and Ticker or Trading Symbol Allovir, Inc. [ ALVR ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify							
	Last) (First) (Mide C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500			3. Date of Earliest Transaction (Month/Day/Year) 02/16/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)  tive Securities Acquired, Disposed of, or Benef							6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)			Zip)												
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date,		3.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of		int of es ially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	d tion(s)		,
Common Stock			02/16/2021			S <sup>(1)</sup>		2,850	D	\$41.81	2,494,317		4,317	I	See Footnote <sup>(3)</sup>
Common Stock			02/16/2021			S <sup>(1)</sup>		200	D	D \$42.79 <sup>(4</sup>	9 <sup>(4)</sup>	2,494,117		I	See Footnote <sup>(3)</sup>
Common Stock			02/17/2021			S <sup>(1)</sup>		500	D	\$38.62	26(5)	2,49	3,617	I	See Footnote <sup>(3)</sup>
Common Stock			02/17/2021			S <sup>(1)</sup>		400	D	\$39.84	99(6)	2,49	3,217	I	See Footnote <sup>(3)</sup>
Common Stock			02/17/2021			S <sup>(1)</sup>		1,386	D	\$41.28	06 <sup>(7)</sup>	2,49	1,831	I	See Footnote <sup>(3)</sup>
Common Stock											28,	,000	D		
		Та	ble II - Derivati (e.g., pu	ve Securit ts, calls, w								Owne	d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Numbor of Derivating Securities Acquires (A) or Dispose of (D) (Instr. 3, and 5)	per 6. Experiments (News)	Date I	Exercisable and on Date Day/Year)	nd 7. Ar Se Ur De Se	Title and mount of ecurities anderlying erivative ecurity (Instant 4)	8. D S. (I	Price of erivative ecurity nstr. 5)	9. Numbo derivativ Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e Owner Form: Direct or Indi g (I) (Ins	(D) Beneficia Ownersh rect (Instr. 4)

## **Explanation of Responses:**

- 1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$41.38 to \$42.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

(D)

(A)

Date Exercisable

Expiration Date

- 3. Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$42.45 to \$43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$38.28 to \$39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$39.59 to \$40.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$41.02 to \$41.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

## Remarks:

/s/ Brett Hagen, as Attorneyin-Fact

Amount Number

of Shares

Title

02/18/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.